GlassScriptPhysician profile
Prateek Sanghera
NPI 1316232820
$7,176.26
in general payments reported to CMS, 2019-2025
32 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $135 · 2021: $886 · 2022: $921 · 2023: $1,718 · 2024: $1,046 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,181 · Consulting Fee: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,180.64 |
| Consulting Fee | $760.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,105.97 | 2019-2025 | Lokelma, Farxiga |
| Merit Medical Systems INC | $919.27 | 2025 | |
| Vifor Pharma, INC. | $706.92 | 2020-2025 | Veltassa, Korsuva |
| Medtronic, INC. | $629.17 | 2022-2024 | Ellipsys Vascular Access System, Argyle |
| Amgen INC. | $569.32 | 2021-2025 | Krystexxa, Tavneos, Aranesp |
| Otsuka America Pharmaceutical, INC. | $507.10 | 2019-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $306.46 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $294.06 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $278.22 | 2019-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $251.55 | 2020-2025 | Benlysta, Jesduvroq, Shingrix |
| Calliditas Therapeutics US INC. | $214.81 | 2022-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $159.12 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $155.48 | 2019-2023 | Ultomiris |
| Lilly USA, LLC | $132.74 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $105.86 | 2021-2025 | Ozempic, Rybelsus |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $82.82 | 2023-2025 | Purified Cortrophin Gel |
| Bard Peripheral Vascular, INC. | $80.59 | 2021-2024 | Pristine, Glidepath |
| Opko Pharmaceuticals, LLC | $77.75 | 2021-2025 | Rayaldee |
| Pharmacosmos Therapeutics INC. | $77.66 | 2021 | |
| Ardelyx, INC. | $64.02 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.27 | 2023-2025 | Jardiance |
| Akebia Therapeutics INC | $61.25 | 2023-2025 | Auryxia, Vafseo |
| Kyowa Kirin, INC. | $57.15 | 2022-2023 | Crysvita |
| Aurinia Pharma U.S., INC. | $50.59 | 2025 | Lupkynis |
| Daiichi Sankyo INC. | $50.26 | 2019-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $43.74 | 2019-2025 | |
| Laminate Medical Technologies INC. | $38.00 | 2025 | Vasq |
| Mallinckrodt Hospital Products INC. | $26.42 | 2024 | Terlivaz |
| Inari Medical, INC. | $19.73 | 2022 | |
| Argon Medical Devices, INC. | $18.19 | 2023 | Cleaner |
| Cormedix INC. | $14.48 | 2024 | Defencath |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.29 | 2023 | Jynarque |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prateek Sanghera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.